Have PDUFA Dates Increased Safety Issues? Study Says Yes, FDA Says No
Executive Summary
FDA is preparing to rebut an analysis published in the New England Journal of Medicine March 27 suggesting that new molecular entities approved close to review deadlines under the Prescription Drug User Fee Act are more likely to suffer post-market safety problems